2016. ISPOR European Congress – Cost-effectiveness analysis of ixekizumab vs. secukinumab in sequential biologic treatment of psoriasis in the UK

Johansson E, Svedbom A, Kumar G, Hartz S, Kiri S. Cost-effectiveness analysis of ixekizumab vs. secukinumab in sequential biologic treatment of psoriasis in the UK. Value Health. 2016 Nov;19(7):A568. Presented at: ISPOR 19th Annual European Congress; November 1, 2016; Vienna, Austria.